CA Patent

CA2625862A1 — Liquid pharmaceutical compositions of nimodipine

Assigned to Transform Pharmaceuticals Inc · Expires 2007-04-26 · 19y expired

What this patent protects

The present invention relates to liquid compositions of nimodipine and administration of said compositions. New stable liquid compositions of nimodipine can be used to treat conditions such as, but not limited to, aneurysms, subarachnoid hemorrhage, vasospastic angina, Prenzmetal…

USPTO Abstract

The present invention relates to liquid compositions of nimodipine and administration of said compositions. New stable liquid compositions of nimodipine can be used to treat conditions such as, but not limited to, aneurysms, subarachnoid hemorrhage, vasospastic angina, Prenzmetal's angina, stable angina, acute myocardial infarction, myocardial arrest, arrhythmia, systemic hypertension, pulmonary hypertension, congestive heart failure, and hypertrophic cardiomyopathy.

Drugs covered by this patent

Patent Metadata

Patent number
CA2625862A1
Jurisdiction
CA
Classification
Expires
2007-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Transform Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.